Aldeyra Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Aldeyra Therapeutics is Todd Brady, benoemd in Jan2012, heeft een ambtstermijn van 12.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.68M, bestaande uit 15.8% salaris en 84.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.94% van de aandelen van het bedrijf, ter waarde € 5.38M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 11.3 jaar.

Belangrijke informatie

Todd Brady

Algemeen directeur

US$3.7m

Totale compensatie

Percentage CEO-salaris	15.8%
Dienstverband CEO	12.8yrs
Eigendom CEO	1.9%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	11.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Todd Brady's beloning veranderd ten opzichte van Aldeyra Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$45m
Jun 30 2024	n/a	n/a	-US$38m
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$4m	US$581k	-US$38m
Sep 30 2023	n/a	n/a	-US$46m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$61m
Dec 31 2022	US$3m	US$559k	-US$62m
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$63m
Dec 31 2021	US$3m	US$547k	-US$58m
Sep 30 2021	n/a	n/a	-US$53m
Jun 30 2021	n/a	n/a	-US$46m
Mar 31 2021	n/a	n/a	-US$39m
Dec 31 2020	US$2m	US$544k	-US$38m
Sep 30 2020	n/a	n/a	-US$39m
Jun 30 2020	n/a	n/a	-US$49m
Mar 31 2020	n/a	n/a	-US$55m
Dec 31 2019	US$4m	US$523k	-US$61m
Sep 30 2019	n/a	n/a	-US$58m
Jun 30 2019	n/a	n/a	-US$50m
Mar 31 2019	n/a	n/a	-US$46m
Dec 31 2018	US$3m	US$506k	-US$39m
Sep 30 2018	n/a	n/a	-US$35m
Jun 30 2018	n/a	n/a	-US$29m
Mar 31 2018	n/a	n/a	-US$26m
Dec 31 2017	US$2m	US$473k	-US$22m

Compensatie versus markt: De totale vergoeding ($USD 3.68M ) Todd } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 782.05K ).

Compensatie versus inkomsten: De vergoeding van Todd is gestegen terwijl het bedrijf verliesgevend is.

CEO

Todd Brady (52 yo)

12.8yrs

Tenure

US$3,684,651

Compensatie

Dr. Todd C. Brady, M.D., Ph D., served as a Director at F-star Therapeutics, Inc from November 20, 2020 to March 2023. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. si...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Todd Brady	CEO, President & Director	12.8yrs	US$3.68m	1.94% € 5.4m
Stephen Machatha	Chief Development Officer	3.8yrs	US$1.59m	0.19% € 520.6k
Michael Alfieri	Principal Financial & Accounting Officer	less than a year	geen gegevens	geen gegevens
David Burke	Head of Investor Relations	no data	geen gegevens	geen gegevens
Laura Nichols	Operations Manager	no data	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 137 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Todd Brady	CEO, President & Director	19.8yrs	US$3.68m	1.94% € 5.4m
Richard Douglas	Independent Chair of the Board	8.2yrs	US$221.98k	0.21% € 582.2k
Ben Bronstein	Independent Director	14.4yrs	US$190.40k	0.047% € 131.6k
Gary Phillips	Independent Director	15.5yrs	US$194.07k	0.025% € 69.0k
Martin Joyce	Independent Director	11.1yrs	US$195.66k	0.040% € 111.6k
Neal Walker	Independent Director	11.4yrs	US$174.22k	0.027% € 73.8k
Jay Duker	Member of Retina Segment Scientific Advisory Board	no data	geen gegevens	geen gegevens
Paul Karpecki	Member of Anterior Segment Scientific Advisory Board	4.8yrs	geen gegevens	geen gegevens
John Sheppard	Member of Anterior Segment Scientific Advisory Board	no data	geen gegevens	geen gegevens
Nancy Miller-Rich	Independent Director	4.8yrs	US$174.22k	0% € 0
Victor Perez	Member of Anterior Segment Scientific Advisory Board	no data	geen gegevens	geen gegevens
David Chu	Member of Anterior Segment Scientific Advisory Board	no data	geen gegevens	geen gegevens

11.3yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 137 zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.3 jaar).

Aldeyra Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Chief Development Officer recently sold €69k worth of stock

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

CEO, President & Director recently sold €532k worth of stock

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023

Insufficient new directors

Insider recently bought €1.1m worth of stock

Recent updates

New minor risk - Profitability

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Chief Development Officer recently sold €69k worth of stock

New major risk - Share price stability

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

New minor risk - Profitability

No longer forecast to breakeven

Aldeyra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Forecast to breakeven in 2026

Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

No longer forecast to breakeven

New minor risk - Profitability

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Profitability

No longer forecast to breakeven

Forecast to breakeven in 2024

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

CEO, President & Director recently sold €532k worth of stock

Forecast to breakeven in 2024

New minor risk - Profitability

Forecast to breakeven in 2024

Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

New minor risk - Profitability

New minor risk - Market cap size

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease

Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc

Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc

Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, Inc

Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough

Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023

Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease Trials

Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

Forecast to breakeven in 2025

Insufficient new directors

Aldeyra Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics, Inc. Announces Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease

Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Part 1 of Phase 3 Guard Trial of Adx-2191 in Proliferative Vitreoretinopathy

Aldeyra Therapeutics, Inc. Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA

Insider recently bought €1.1m worth of stock

Aldeyra Therapeutics, Inc. Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial

CEO, President & Director recently bought €57k worth of stock

Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Phase 3 Tranquility-2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease

Aldeyra Therapeutics, Inc. Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease

Aldeyra Therapeutics, Inc. Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease

Aldeyra Therapeutics Announces That Post-Hoc Analysis Using Computer Automated Grading of Phase 3 Tranquility Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap over Vehicle for Primary Endpoint of Ocular Redness

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 07, 2022

Aldeyra Therapeutics, Inc. Announces Completion of Enrollment in Phase 3 Tranquility-2 Trial in Patients with Dry Eye Disease

Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day

No longer forecast to breakeven

Aldeyra Therapeutics, Inc. Initiates Phase 2 Clinical Trial of ADX-2191 for the Treatment of Retinitis Pigmentosa

Forecast to breakeven in 2024

Aldeyra Therapeutics, Inc. Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model

Forecast to breakeven in 2024

Aldeyra Therapeutics, Inc Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra

Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease

Aldeyra Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 Invigorate Clinical Trial of Reproxalap in Allergic Conjunctivitis

Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design